India will carry out a deeper review of post-vaccination side effects from the AstraZeneca shot next week although no cases of blood clots have been reported so far, an official told AFP.
New Delhi decided to conduct the review after several countries suspended rollout over blood clot fears even as the World Health Organisation said there was no reason to stop using AstraZeneca's Covid-19 jab.
Denmark, Norway and Iceland paused use of the drugmaker's shot as a precaution after isolated reports of recipients developing blood clots.
“We are looking at all the adverse events, particularly serious adverse events like deaths and hospitalisation. We will come back if we find anything of concern,” N.K. Arora, a member of India's national task force on Covid-19, told AFP.